NINDS Specific Program/Budget Information

Limited Amount of Award

For the Omnibus and Program Announcements released after August 6, 2012:

According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.  With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% ($225,000 for Phase I and $1,500,000 for Phase II, a hard cap). Applicants are strongly encouraged to contact program officials prior to submitting any application. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. For details see PHS 2013-2.

For Program Announcements released prior to August 6, 2012:

For budgetary, administrative, or programmatic reasons, NINDS may decrease the length of an award and/or the budget, or not fund an application. Generally, NINDS does not fund Phase I applications greater than $350,000 total cost per year for up to 2 years or Phase II applications greater than $1,000,000 total cost per year for up to 3 years. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application. For details see PHS 2012-2.

Phase IIB Competing Renewal Awards

In addition to the traditional Phase I and II applications, NINDS accepts Phase IIB SBIR/STTR Competing Renewal applications through specific opportunities that focus on the commercialization of SBIR and STTR developed technologies. These opportunities can be found on the NIH SBIR web page.

Clinical Trials

The NINDS is committed to identifying effective treatments for neurological disorders by supporting well-executed clinical trials. NINDS will not accept unsolicited SBIR/STTR applications that include clinical trials under the Omnibus solicitation. A clinical trial is a prospective biomedical or behavioral research study of human subjects designed to answer specific questions about the safety, tolerability, efficacy and/or effectiveness of pharmacologic, behavioral, biologic, surgical, or device interventions. This policy does not apply to (1) exploratory IND studies as defined by the FDA or (2) early feasibility studies of devices as defined by the FDA.

NINDS accepts and supports SBIR and STTR clinical trial applications through specific funding opportunities, which can be found on the NINDS SBIR web page.  Other human subjects research can also be submitted through the Omnibus solicitation. NINDS may decline funding of any application that includes human subjects for programmatic or administrative reasons. SBIR applicants considering projects involving human subjects research are strongly encouraged to contact Stephanie Fertig or Joanne Odenkirchen (contact information provided below) within the NINDS Office of Clinical Research.

Program Contact

Stephanie Fertig, M.B.A.
Small Business Program
National Institute of Neurological Disorders and Stroke
National Institutes of Health
NSC, Room 2228
6001 Executive Blvd.
Bethesda, MD 20892-9521
(Courier:  Rockville, MD 20852)
Tel: (301) 496-1779
Fax: (301) 480-1080

Clinical Trials Contact

Joanne C Odenkirchen, MPH
Office of Clinical Research
National Institute of Neurological Disorders and Stroke
National Institutes of Health
NSC, Room 2178
6001 Executive Blvd.
Bethesda, MD 20892-9521
(Courier:  Rockville, MD 20852)
Tel: (301) 496-3104
Fax: (301) 480-1080